Polypeptide delivery system

a delivery system and polypeptide technology, applied in the field of expression constructs, can solve the problems of destroying implanted cells, restricting industry-wide adoption, and reducing and achieve the effect of improving the gene delivery system and increasing the secretion of heterologous gene products

Inactive Publication Date: 2006-03-23
COMMONWEALTH SCI & IND RES ORG +2
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0004] The present inventors have now found that ligation of an insulin secretory signal to a heterologous gene sequence prior to introduction of the gene sequence into a host cell results in a surprising increase in the level of secretion of the heterologous gene product. This finding has led to the development of an improved gene delivery system involving encapsulation of recombinant cells for implantation into a host.
[0021] It will be appreciated by those skilled in the art that the present invention provides an improved system for the delivery of genetic material to a host. The ligation of the insulin secretory signal to a biologically active polypeptide leads to increased secretion of the polypeptide from recombinant cells. Following secretion, the secretory signal may be cleaved leaving the biologically active polypeptide. The recombinant cells, when encapsulated in a semi-permeable membrane, have the capacity to secrete significant amounts of the biologically active polypeptide and the semi-permeable membrane enables control of gene expression by external means. Implantation of the encapsulated recombinant cells provides an advantage in that the implantation requires minimal surgery. Further, the semi-permeable membrane reduces immune surveillance and cell rejection which means that non-host cells can be employed in the capsule.
[0022] In a preferred embodiment, the semi-permeable membrane is durable which provides an advantage in that it may limit cell growth thereby preventing uncontrolled proliferation in the recipient host. The capsules provide a further advantage in that they may be removed and re-used.

Problems solved by technology

Unfortunately, somatotropin (which is a small protein of 190 amino acids) is susceptible to gastric acids and protein digestion hence daily injections are required in order to be efficacious.
Currently, welfare and ethical issues discourage the use of the pneumatic pST injection gun and the costs of daily administration restrict industry-wide adoption.
Further, if the capsule is damaged by severe tissue trauma a normal host-graft rejection would destroy the implanted cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide delivery system
  • Polypeptide delivery system
  • Polypeptide delivery system

Examples

Experimental program
Comparison scheme
Effect test

example 1

Cloning of the ISS-pST Construct

[0039] The pST gene was obtained from Southern Cross Biotechnology Pty Ltd in an E. coli bacterium. The plasmid containing the pST gene, pMG939, was isolated from the bacterium using standard plasmid preparation techniques. The PCR primers were designed to amplify the pST gene, add an Xho I site to the 5′ end and an Xba I site to the 3′ end to enable ligation events.

[0040] The modified pST gene sequence was subsequently ligated to a secretory signal sequence (ISS) derived from the preproinsulin cDNA. Nhe I (GCTAGC) and Xba I (TCTAGA) restriction sites were constructed in front of the ISS start codon and after the 3′ terminal codon of pST, respectively, to allow incorporation into the pCI-neo plasmid (Promega). The pST fusion construct was subsequently isolated and sequenced to verify the coding region (FIG. 1).

[0041] Transfection of rat myoblast (L6) cells (pST gene incorporation into cells) was performed, with LipoTAXI (Stratagene), 2 hrs after th...

example 2

Preparation of the Porcine Somatotropin-Rat Myoblast (L6) Immunoneutral Expression System (pST-L6IXS)

[0043] The encapsulation procedure described in Basic et al, 1996, was followed with the following modifications.

[0044] Encapsulation of cells at room temperature, utilises calcium chloride (or lactate) [100 mM] to gel the alginate [1.5% w / v] droplets followed immediately by washing with saline (0.9% NaCl) then resuspending in poly-L-lysine [0.05%] for 5 min. Calcium chloride crosslinking for 10 min at 37° C. resulted in an alginate matrix that was more compatible with cell viablity.

[0045] After the poly-L-lysine coating and saline washes another alginate layer is added. Sodium citrate [55 mM] treatment for 4 min at room temperature softens the capsule to a consistency that increases the difficulty of further manipulation. Cell viablity is apparently reduced to 98%.

[0046] Procedural and equipment modifications to the encapsulation protocol improved the efficiency (time and resour...

example 3

Pilot Experiment (1) Involving Implantation of pST-L6IXS in Pigs

[0047] Preliminary results obtained with the pST-L6IXS, administered to growing mice, indicate enhanced growth characteristics. In a pilot experiment with male pigs (n=9, mean live weight 61 kg) varying numbers of pST-L6IXS were administered in different sites (3 capsules, i.m. in the neck muscle, 3 capsules s.c. in the neck, 10 capsules s.c. at the base of the ear, 20 capsules i.m. in the neck or 29 capsules i.m. in the neck of individual animals on day 0). Blood samples (10 ml) were collected via jugular venipuncture and P2 ultra-sound (us) measurements were recorded at −14, 0, 7, 14, 21, 28 and 36 days post administration. The sites of pST-L6IXS administration were monitored for tissue reaction events throughout the experiment. On day 36 animals were euthanased and carcass analysis (back fat depth, BF(mm); eye muscle area, EMA(cm); forearm bone length, BONE(cm); heart weight, HEART(gm); spleen weight, SPLEEN(gm) and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
concentrationsaaaaaaaaaa
mean live weightaaaaaaaaaa
Login to view more

Abstract

An expression construct is disclosed which is useful for delivering an exogenous polypeptide (e.g. a growth hormone such as somatotropin) to a host. In one application of the invention, the expression construct is introduced into a non-host recombinant cell encapsulated in a semi-permeable membrane for implantation into the host. The semi-permeable membrane inhibits immune surveillance and cell rejection events so that non-host, highly expressing, recombinant cells can be used.

Description

FIELD OF THE INVENTION [0001] The present invention relates to an expression construct for delivering an exogenous polypeptide to a host. The present invention also relates to recombinant cells which include this expression construct and to semi-permeable capsules which include the recombinant cells. BACKGROUND OF THE INVENTION [0002] In mammals, somatotropin (growth hormone) is normally secreted from the pituitary gland. However, exogenous administration of somatotropin to pigs has been shown to improve feed efficiency 15-20%, increase daily weight gain 10-15%, reduce carcass fat 10-20%, increase lean meat content 5-10% and reduce feed intake. Unfortunately, somatotropin (which is a small protein of 190 amino acids) is susceptible to gastric acids and protein digestion hence daily injections are required in order to be efficacious. Currently, welfare and ethical issues discourage the use of the pneumatic pST injection gun and the costs of daily administration restrict industry-wide...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K48/00C12N5/06C12N5/08C12N15/87A61K9/48C12N15/09A61K38/00A61K38/27A61K47/42A61K47/48A61P3/00A61P5/02A61P37/04A61P43/00C12N5/10C12N11/04C12N15/85C12P21/02C12R1/91
CPCA61K38/27C12N15/85A61K48/00A61P3/00A61P37/04A61P43/00A61P5/02C12N15/63
Inventor KEEGAN, MITCHELLJONES, MARKMOORE, GEOFFREY
Owner COMMONWEALTH SCI & IND RES ORG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap